Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas
Tóm tắt
The management of patients with treated malignant lymphomas requires functional methods to differentiate a residual soft tissue mass. Patients with treated Hodgkin's lymphoma (HL,n = 20, 68 malignant lesions, three benign lesions) or non-Hodgkin's lymphoma (NHL,n = 26, 46 malignant lesions, one benign lesion) were studied with positron emission tomography (PET) and fluorine-18 deoxyglucose (FDG). Oxygen-15 labelled water was used (n = 14, 25 lesions) in addition to FDG in order to obtain information on the tissue perfusion. Long-term follow-up studies with PET and FDG were performed in nine patients up to 511 days after the initiation of second-line therapy. Fourteen patients underwent single-photon emission tomography (SPET) with technetium-99m sestamibi immediately prior to the first PET examination. PET with FDG displays a high sensitivity for the detection of viable tumour tissue, all the malignant lesions being correctly classified in this study. The possible limitations are inflammatory processes, which may obscure tumour detection due to increased FDG uptake, and malignant lesions with low FDG uptake due to reduced perfusion. Difficulties exist in the prognosis of long-term response, since the change in FDG uptake may be variable. Long-term therapy outcome was correlated with the slope values obtained from the standardized integral uptake (SIU) data, which provides a new approach for the evaluation of PET follow-up studies.99mTc-sestamibi, which should reflect the multidrug resistance, was evaluated with respect to therapy outcome. A high uptake of99m-Tc-sestamibi was observed in patients with stable disease or better. The data support the hypothesis that sestamibi may reflect multidrug resistance. Due to technical limitations of the SPET technique, the use of a positron-labelled compound would be superior to SPET for clinical application.
Tài liệu tham khảo
Strauss LG, Clorius JH, Schlag P, et al. Recurrence of colorectal tumours: PET evaluation.Radiology 1989;170:329–332.
Strauss LG, Conti PS. The applications of PET in clinical oncology.J Nucl Med 1991;32:623–648.
Dimitrakopoulou A, Strauss LG, Clorius JH, et al. Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma.J Nucl Med 1993;34:1075–1081.
Piwnica-Worms D, Chin ML, Budding M, et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.Cancer Res 1993;53:977–984.
Del Fiore F, Depresseux JC, Bartsch P, Quaglia L, Peters JM. Production of oxygen-15, nitrogen-13 and carbon-11 and of their low molecular weight derivatives for biomedical applications.Int J Appl Radiat Isot 1979;30:543–549.
Toorongian SA, Mulholland GK, Jewett DM, Bachelor MA, Kilbourn MR. Routine production of 2-deoxy-2-[18F]fluoro-Dglucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin.Nucl Med Biol 1990;3:273–279.
Strauss LG. Positron emission tomography for therapy management. In: Breit A, Heuck A, Lukas P, Kneschaurek P, Mayr M, eds.Tumor response monitoring and treatment planning, 1st edn. Berlin Heidelberg New York: Springer;1992:25–28.
Sasaki M, Ichiya Y, Kuwabara Y, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in technetium99m-hydroxymethylenediphosphate negative bone tumours.J Nucl Med 1993;34:288–290.
Bares R, Altehoefer C, Cremerius U, et al. FDG-PET for metabolic classification of residual lymphoma masses after chemotherapy [abstract].J Nucl Med 1994;35:131P.
Strauss LG. Application of positron emission tomography in colorectal carcinoma. Onkologie 1993;16:232–244.
Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity.J Nucl Med 1992;33:325–329.
Higashi K, Clavo A, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake.J Nucl Med 1993;34:414–419.
Brown RS, Fisher SJ, Wahl RL. Autoradiographic evaluation of the intratumoural distribution of 2-deoxy-D-glucose and monoclonal antibodies in xenografts of human ovarian adenocarcinoma.J Nucl Med 1993;34:75–82.
Kubota K, Kubota R, Yamada S. FDG accumulation in tumour tissue.J Nucl Med 1993;34:419–421.
Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Active and passive mechanisms of [fluorine-18]fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: a microautoradiographic study.J Nucl Med 1994;35: 1067–1075.
Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoural distribution of fluorine- 18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography.J Nucl Med 1992;33:1972–1980.
Hoffman JM, Waskin HA, Schifter T, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS.J Nucl Med 1993;34:567–575.
Sasaki M, Ichiya Y, Kuwabora Y, et al. Ringlike uptake of [18F]FDG in brain abscess: a PET study.J Comput Assist Tomogr 1990;14:486–487.
Longo DL. The use of chemotherapy in the treatment of Hodgkin's disease.Semin Oncol 1990:17:716–735.
Okada J, Yoshikawa K, Imazeki K, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis.J Nucl Med 1991;32: 686–691.
Wylie BR, Southee AE, Joshua DE, et al. Gallium scanning in the management of mediastinal Hodgkin's disease.Eur J Haematol 1989;42:344–347.
Israel O, Front D. Benign mediastinal and parahilar uptake of gallium-67 in treated lymphoma: Do we have all the answers?J Nucl Med 1993;34:1330–1331.
Dimitrakopoulou A, Strauss LG, Knopp MV, et al. Positron emission tomography measurement of fluorouracil uptake prior to therapy and chemotherapy response. In: Breit A, Heuck A, Lukas P, Kneschaurek P, Mayr M, eds.Tumor response monitoring and treatment planning, 1st edn, Berlin Heidelberg New York: Springer;1992:219–222.
Wolf W, Presant CA, Servis KL, et al. Tumor trapping of 5fluorouracil: In vivo19F NMR spectroscopic pharmacokineties in tumour-bearing humans and rabbits.Proc Natl Acad Sci USA 1990:87:492–496.
Mattern J, Volm M. Multiple pathway drug resistance (review).Int J Oncol 1993;2:557–561.
Ishikawa T, Müller M, Klünemann C, Schaub T, Keppler D. ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates.J Biol Chem 1990;265:191279–191286.
Kadmon M, Klünemann C, Böhme M, et al. Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from hepatocyte into bile.Gastroenterology 1993;104:1507–1514.
Keppler D. Leukotrienes: biosynthesis, transport, inactivation and analysis.Rev Physiol Biochem Pharmacol 1992;121:1–30.
Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in tumour cells.Pharmacol Rev 1990;42:155–199.